A multimodal machine learning model for predicting dementia conversion in Alzheimer's disease.

Journal: Scientific reports
Published Date:

Abstract

Alzheimer's disease (AD) accounts for 60-70% of the population with dementia. Mild cognitive impairment (MCI) is a diagnostic entity defined as an intermediate stage between subjective cognitive decline and dementia, and about 10-15% of people annually convert to AD. We aimed to investigate the most robust model and modality combination by combining multi-modality image features based on demographic characteristics in six machine learning models. A total of 196 subjects were enrolled from four hospitals and the Alzheimer's Disease Neuroimaging Initiative dataset. During the four-year follow-up period, 47 (24%) patients progressed from MCI to AD. Volumes of the regions of interest, white matter hyperintensity, and regional Standardized Uptake Value Ratio (SUVR) were analyzed using T1, T2-weighted-Fluid-Attenuated Inversion Recovery (T2-FLAIR) MRIs, and amyloid PET (αPET), along with automatically provided hippocampal occupancy scores (HOC) and Fazekas scales. As a result of testing the robustness of the model, the GBM model was the most stable, and in modality combination, model performance was further improved in the absence of T2-FLAIR image features. Our study predicts the probability of AD conversion in MCI patients, which is expected to be useful information for clinician's early diagnosis and treatment plan design.

Authors

  • Min-Woo Lee
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea.
  • Hye Weon Kim
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea.
  • Yeong Sim Choe
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea.
  • Hyeon Sik Yang
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea.
  • Jiyeon Lee
    Department of Brain and Cognitive Engineering, Korea University, Seoul, Republic of Korea.
  • Hyunji Lee
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea.
  • Jung Hyeon Yong
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea.
  • Donghyeon Kim
  • Minho Lee
    School of Electronics Engineering, Kyungpook National University, 1370 Sankyuk-Dong, Puk-Gu, Taegu 702-701, Republic of Korea. Electronic address: mholee@gmail.com.
  • Dong Woo Kang
    Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
  • So Yeon Jeon
    Department of Psychiatry, Chungnam National University Hospital, Daejeon, 35015, Republic of Korea.
  • Sang Joon Son
    Department of Psychiatry, School of Medicine, Ajou University, Suwon, Gyeonggi-do, Republic of Korea.
  • Young-Min Lee
    Department of Psychiatry, Pusan National University School of Medicine, Pusan National University, Busan, 49241, Republic of Korea.
  • Hyug-Gi Kim
    Department of Biomedical Engineering, Graduate School, Kyung Hee University, 1732, Deogyeong-daero, Giheunggu, Yongin-si, Gyeonggi-do 446-701, Korea.
  • Regina E Y Kim
    Research Institute, Neurophet Inc., Seoul, 06234, Republic of Korea. reginaeunyoungkim@neurophet.com.
  • Hyun Kook Lim
    Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10 63-ro, Yeongdeungpo-gu, Seoul, 07345, Korea. drblues@catholic.ac.kr.